论文部分内容阅读
目的分析甲状腺乳头状癌(papillary thyroid cancer,PTC)患者ERβ_2表达与不同生物标志物和临床病理因素之间关系。方法选择2015年8月—2016年8月本院采集的106例PTC患者肿瘤组织,采用免疫组织化学染色方法检测其中ERβ_2表达情况,分析ERβ_2表达与不同生物标志物和临床病理因素之间关系。采用Allred评分法对ERβ_2、Ki-67、突变体p53和VEGF免疫组织化学染色进行评分。计数资料采用χ2检验,P<0.05为差异有统计学意义。结果 105例患者(99.06%)为ERβ_2细胞核表达阳性,1例患者(0.94%)为细胞核和细胞质表达阳性。106例患者免疫组织化学染色得分情况如下:3分患者3例(2.8%)、4分患者9例(8.5%)、5分患者5例(8.5%)、6分患者30例(28.3%)、7分患者34例(32.1%)、8分患者21例(19.8%)。高龄生育的妇女患者中ERβ_2表达与Ki-67表达密切相关(r=0.443,P<0.05)。在适龄生育的男性患者中ERβ_2表达与VEGF表达密切相关(r=0.495,P<0.05)。然而ERβ_2表达与突变体p53无相关性(P>0.05)。此外,不同年龄段和性别患者中ERβ_2表达与患者肿瘤大小、是否存在甲状腺肿大和TNM分期等无相关性(P>0.05)。然而,与适龄生育未出现淋巴结转移的女性患者相比,淋巴结转移的女性患者ERβ_2表达显著下降(Z=-2.107,P<0.05)。结论本研究结果表明PTC患者ERβ_2表达与疾病进展密切相关,其作用根据患者体内雌激素水平变化而变化。
Objective To analyze the relationship between ERβ_2 expression and different biomarkers and clinicopathological factors in patients with papillary thyroid cancer (PTC). Methods Tumor tissue from 106 PTC patients collected in our hospital from August 2015 to August 2016 was collected. The expression of ERβ_2 was detected by immunohistochemical staining, and the relationship between ERβ_2 expression and different biomarkers and clinicopathological factors was analyzed. The Allred score was used to evaluate the expression of ERβ_2, Ki-67, p53 and VEGF in the specimens. Count data using χ2 test, P <0.05 for the difference was statistically significant. Results 105 patients (99.06%) were positive for ERβ 2 nucleus, and 1 (0.94%) were positive for nucleus and cytoplasm. The scores of immunohistochemical staining in 106 patients were as follows: 3 patients (2.8%) in 3 patients, 9 patients (8.5%) in 4 patients, 5 patients (8.5%) in 5 patients and 30 patients (28.3%) in 6 patients , 34 patients (32.1%) in 7 patients and 21 patients (19.8%) in 8 patients. ERβ_2 expression was closely related to the expression of Ki-67 in elderly women (r = 0.443, P <0.05). ERβ_2 expression was closely related to the expression of VEGF in male patients of childbearing age (r = 0.495, P <0.05). However, there was no correlation between ERβ_2 expression and mutant p53 (P> 0.05). In addition, there was no correlation between ERβ_2 expression and tumor size, presence of goiter and TNM staging in different age groups and gender (P> 0.05). However, ERβ_2 expression was significantly decreased in women with lymph node metastases (Z = -2.107, P <0.05), compared with women without lymph node metastases at childbearing age. Conclusions The results of this study suggest that the expression of ERβ_2 in PTC patients is closely related to the progress of the disease. The role of ERβ_2 in patients with PTC varies according to the level of estrogen in the patients.